» Articles » PMID: 23948935

RNA Interference-mediated Knockdown of Long-form Phosphodiesterase-4D (PDE4D) Enzyme Reverses Amyloid-β42-induced Memory Deficits in Mice

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2013 Aug 17
PMID 23948935
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Phosphodiesterase-4 (PDE4) inhibitors enhance memory, increase hippocampal neurogenesis, and reverse amyloid-β (Aβ)-induced memory deficits. Here, we examined whether long-form PDE4D knockdown by lentiviral RNA construct containing a specific microRNA/miRNA-mir hairpin structure (4DmiRNA) reversed memory impairment caused by amyloid-β1-42 (Aβ42) in mice using the Morris water maze (MWM) and novelty object recognition tests. Western blotting analysis was used to assess protein levels of cAMP response element-binding protein (CREB, unphosphorylated and phosphorylated [pCREB]), brain-derived neurotrophic factor (BDNF), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and nuclear factor-κB (NF-κB) to explore the neurochemical mechanisms. Aggregated Aβ42 (0.5 μg/side) bilaterally infused in dentate gyrus decreased cAMP levels (p < 0.01) and produced memory deficits in the MWM (p < 0.01) and object recognition tests (p < 0.01). Microinfusions of lentiviruses resulted in downregulated expression of PDE4D4 and 4D5 proteins and reversed Aβ42-induced cAMP decline (p < 0.05) and memory deficits. Treatment also concomitantly increased pCREB (p < 0.05) and BDNF (p < 0.01) and reduced IL-1β (p < 0.05), TNF-α (p < 0.01), and NF-κB (p65) (p < 0.05) in the hippocampus of Aβ42-challenged mice. These results suggest that long-form PDE4D knockdown may offer a promising treatment for memory loss associated with Alzheimer's disease.

Citing Articles

Phosphodiesterase 4 inhibition as a novel treatment for stroke.

Zhong J, Yu X, Lin Z PeerJ. 2025; 13:e18905.

PMID: 39897494 PMC: 11786714. DOI: 10.7717/peerj.18905.


Investigating the Therapeutic Mechanisms of Total Saikosaponins in Alzheimer's Disease: A Metabolomic and Proteomic Approach.

Wei H, Du T, Zhang W, Ma W, Yao Y, Li J Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861162 PMC: 11768985. DOI: 10.3390/ph18010100.


Research progress on phosphodiesterase 4 inhibitors in central nervous system diseases.

Adili A, Dilihumaer A, Zhu H, Tang H Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(3):390-398.

PMID: 38860393 PMC: 11348698. DOI: 10.3724/zdxbyxb-2024-0023.


Allosteric inhibition of phosphodiesterase 4D induces biphasic memory-enhancing effects associated with learning-activated signaling pathways.

Jino K, Miyamoto K, Kanbara T, Unemura C, Horiguchi N, Ago Y Psychopharmacology (Berl). 2023; 241(4):805-816.

PMID: 38114603 DOI: 10.1007/s00213-023-06510-8.


Biologic that disrupts PDE11A4 homodimerization in hippocampus CA1 reverses age-related cognitive decline of social memories in mice.

Pilarzyk K, Capell W, Porcher L, Rips-Goodwin A, Kelly M Neurobiol Aging. 2023; 131:39-51.

PMID: 37572526 PMC: 10528525. DOI: 10.1016/j.neurobiolaging.2023.07.008.